Press Releases

“Safeguarding public health must be number one priority” for EU27 and UK Government in phase two of Brexit talks

To coincide with today’s House of Commons Health Select Committee on ‘Brexit: the regulation of medicines, medical devices and substances of human origin’, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have published new research on the public health implications of Brexit.

BIA reacts to announcement from European Commission President Jean-Claude Juncker and Prime Minister Theresa May that ‘sufficient progress’ has been agreed on phase one of the Brexit negotiations. 

CEO, Steve Bates, said: “We welcome today’s agreement. It is now crucial that the UK and EU agree a transition period to ensure that the supply of medicines to patients in the UK and across Europe is not affected. Public health and health security should be the first priority for the second phase of talks and we stand ready as a unified life science sector to provide expert input on such a process".

BIA CEO Steve Bates responds to the announcement of the Life Sciences Sector Deal

Responding to today’s announcement of the Life Sciences Sector Deal, BIA CEO, Steve Bates, said: “It is fantastic that the life sciences is the first sector to have a deal published and this document showcases a range of investment in to the industry and partnerships working across this exciting and entrepreneurial industry. BIA members are particularly prominent in advanced therapies manufacturing and genomics."

Peter Dunnill Lifetime Achievement Award and Richard Wilson Impact Award winners announced for the bioProcessUK conference

The winners of this year’s Peter Dunnill Lifetime Achievement Award and Richard Wilson Impact Award have been announced today ahead of the 2017 bioProcessUK conference, taking place in Cardiff between 28-30 November.

 

Member News

Medherant completes £3.8 million funding round

Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company as it progresses its ibuprofen TEPI Patch® into clinical development in early 2018.

Tissue Science and Regenerative Medicine

9th International Conference on Tissue Science and Regenerative Medicine is mainly based on the theme “Exploring the frontiers in tissue science and Medicine’’ We warmly welcome all the participants of world’s leading Scientists, Researchers and Scholars. We provide a platform for young researchers and students to present their research through oral presentations through which they can develop a foundation for collaboration among young researchers.

Arecor announces successful vaccine stabilising formulation technology to more effectively combat two major diseases of livestock in the developing world

Cambridge, UK., 8th December 2017: Arecor Ltd (“the Company”), a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, ArestatTM, is pleased to announce that the Company, in partnership with, GALVmed (www.galvmed.org), has successfully applied its vaccine formulation technology to stabilise liquid formulations of vaccines to combat two major diseases of livestock in the developing world.

Domainex appoints Chris Brown as Chief Financial Officer

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Chris Brown has been appointed Chief Financial Officer with immediate effect.

 

BIA blog

Brexit and Trade – Implications for the Life Sciences Sector

Hardly talked about before the EU referendum, trade has become an increasingly hot topic ever since. With EU leaders expected to formally decide that the Brexit negotiations will move to discuss the UK-EU future trading relationship (“Phase II”) at the end of the week, this month is no different. Meanwhile, the UK government is getting ready to transition from the EU’s common commercial policy to its own independent trade policy through the Trade Bill, which is currently progressing through Parliament.

CEO Update: Monday 11 December

Last week, we saw the release of the highly anticipated Life Sciences Sector Deal from government, and it was fantastic to see that ours is the first sector to have a deal published – a clear recognition of our industry’s importance to the future growth and prosperity of the country.

Video of the Week: How does the NHS in England work? An alternative guide

As part of their 'An alternative guide' series, the King's Fund have produced a handy and easy to understand animation on the NHS in England. This short video is a whistle-stop tour of how the NHS works in 2017 and how it’s changing.

50 Movers and Shakers Challenging the Status Quo in BioBusiness

By Miranda Weston-Smith, Founder, BioBeat

 

Our publications

Influencing and shaping our sector, BIA update: July – October 2017

his quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from July to October 2017. Brexit, the government’s Industrial Strategy and a potential sector deal have been keeping all of us at the BIA very busy this quarter.

Growing the next generation of UK management talent

BIA directory of industry training opportunities to help build the next generation of management talent.

A vision for the UK life sciences sector in 2025

This vision, developed in consultation with the BIA Board and sector experts, sets out an ambitious goal for the UK to become a top global cluster in life sciences by 2025.